Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. Clinical-stage biopharmaceutical company Arbutus Biopharma Corp. (ABUS:NASD...
Streetwise Reports | May 20, 2020 |

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. Assembly Biosciences Inc (ASMB:NASDAQ) announced in a press release on October 16, 2019, ...
Streetwise Reports | October 17, 2019 |

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication

A study description and expected data readouts this year are provided in a ROTH Capital Partners report. In a July 8 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Enanta Pharmaceuticals Inc. (ENTA:NASDAQ) kicked off Q2/19 by...
Streetwise Reports | July 11, 2019 |

Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'

The key business and investment points are presented in a ROTH Capital Partners report. In a Dec. 18 research note, analyst Jonathan Aschoff reported that ROTH Capital Partners initiated coverage on Inovio Pharmaceuticals Inc. (INO:NASDAQ) with a Buy rating and a "c...
Streetwise Reports | December 27, 2019 |

Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'

The specifics and benefits of the deal are discussed in an H.C. Wainwright & Co. report. In a July 22 research note, H.C. Wainwright & Co. analyst Ed Arce reported that DURECT Corp. (DRRX:NASDAQ) entered an agreement concerning its SABER technology and SAB...
Streetwise Reports | July 24, 2019 |

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

This California company expects results from clinical trials in liver disease and psoriasis in 2019. In a March 8 research note, H.C. Wainwright & Co. analyst Ed Arce reported that DURECT Corp. (DRRX:NASDAQ) continues advancing clinical trials evaluating its lead prod...
Streetwise Reports | March 14, 2019 |

Vir Biotech Shares Rise on Joint Research Efforts with the NIH to Combat Coronaviruses

Vir Biotechnology shares traded higher after the company reported that it has entered into a research collaboration with the National Institutes of Health Vaccine Research Center on antibodies against coronaviruses including SARS-CoV-2. Clinical-stage immuno...
Streetwise Reports | March 12, 2020 |

Vir Partners with Samsung Biologics on Large-Scale Manufacture of COVID-19 Antibody Treatment

Vir Biotechnology reported it has entered into an agreement with Samsung Biologics valued at $362 million for large-scale manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Though U.S. markets are closed for the Good Friday holiday, Samsung Biologics shar...
Streetwise Reports | April 13, 2020 |